Nasdaq · Healthcare
CYTOKINETICS INC (CYTK)
As-reported financials and recent SEC filings for CYTOKINETICS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$88.0M
Net income
$-785.0M
Net margin
—
Diluted EPS
$-6.54
ROE
119.0%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $-612.3M | $-536.2M | $-496.2M | $-324.2M | $-186.3M |
| Net income | $-785.0M | $-589.5M | $-526.2M | $-389.0M | $-215.3M |
| Diluted EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →1442026-07-01
View on EDGAR →1442026-06-29
View on EDGAR →42026-06-29
View on EDGAR →42026-06-29
View on EDGAR →1442026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on CYTK
Search CYTOKINETICS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.